LoginSignup
RPR

Royalty Pharma Stock

StockStock
ISIN: GB00BMVP7Y09
Ticker: RPRX
GB00BMVP7Y09
RPRX

Price

Historical dividends and forecast

All dividend data

Royalty Pharma has so far distributed $0.63 in 2024. The next dividend will be paid on 10.12.2024

$0.678

CHART BY

Frequently asked questions

What is Royalty Pharma's market capitalization?

The market capitalization of Royalty Pharma is $15.32B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is Royalty Pharma's Price-to-Earnings (P/E) ratio?

The Price-to-Earnings (P/E) ratio (TTM) for Royalty Pharma is 10.16. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.

What is the Earnings Per Share (EPS) for Royalty Pharma?

Royalty Pharma's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $2.558. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Royalty Pharma's stock?

Currently, 8 analysts cover Royalty Pharma's stock, with a consensus target price of $44.33. Analyst ratings provide insights into the stock's expected performance.

What is Royalty Pharma's revenue over the trailing twelve months?

Over the trailing twelve months, Royalty Pharma reported a revenue of $2.27B.

Is Royalty Pharma paying dividends?

Yes, Royalty Pharma is paying dividends. The next payment is scheduled for 10.12.2024, with an expected amount of .

What is the EBITDA for Royalty Pharma?

Royalty Pharma's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $1.54B. EBITDA measures the company's overall financial performance.

What is the free cash flow of Royalty Pharma?

Royalty Pharma has a free cash flow of -$584.58M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Royalty Pharma's stock?

The 5-year beta for Royalty Pharma is 0.45. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Royalty Pharma have, and what sector and industry does it belong to?

Royalty Pharma employs approximately 89 people. It operates in the Health Care sector, specifically within the Misc. Financial Services industry.

What is the free float of Royalty Pharma's shares?

The free float of Royalty Pharma is 380.91M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $15.32B

5Y beta

 0.45

EPS (TTM)

 $2.558

Free Float

 380.91M

P/E ratio (TTM)

 10.16

Revenue (TTM)

 $2.27B

EBITDA (TTM)

 $1.54B

Free Cashflow (TTM)

 -$584.58M

Pricing

1D span
$25.80$26.20
52W span
$25.20$31.66

Analyst Ratings

The price target is $44.33 and the stock is covered by 8 analysts.

Buy

6

Hold

2

Sell

0

Information

Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.

89

Misc. Financial Services

Health Care

Identifier

ISIN

GB00BMVP7Y09

Primary Ticker

RPRX

Knockouts

Join the conversation
Sign upLogin